SNX281

SNX281 is a systemically active non-CDN STING agonist that binds to the STING protein. SNX281 promotes signal transduction of the cGAS-STING pathway, and increases cellular responses to tumor cells. SNX281 activates STING and leads to the production of type I IFNs and proinflammarory cytokines, ultimately stimulating the infilatration of immune cells into the tumor microenvironment. SNX281 enhances anti-tumor immunity, potentially overcoming resistance to checkpoint inhibitors in some cancer. SNX281 can be used in the research for anti-tumor immunity[1][2].

Product Specifications

CAS Number

[2332803-84-4]

UNSPSC

12352005

Target

IFNAR; STING

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/snx281.html

Concentration

10mM

Purity

99.08

Solubility

DMSO : 15 mg/mL (ultrasonic)

Smiles

O=C(CN1C2=CC(C(C)(C)C)=CC=C2C(C3=CC=C(C(SC)=C31)Cl)=O)O

Molecular Formula

C20H20ClNO3S

Molecular Weight

389.90

References & Citations

[1]Catherine SCHOLZ, et al. Biomarkers for sting agonists and methods of using the same. WO2023039363A1.2022-09-02|[2]Wang, B., et al., (2024) . Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects. Frontiers in immunology, 15, 1485546.